Piper Sandler's analysts increased the price target for Becton Dickinson (NYSE:BDX) shares to $280 from $275, while ...

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Becton Dickinson (BDX – Research Report), with a price ...

Piper Sandler raised the firm’s price target on Becton Dickinson (BDX) to $280 from $275 and keeps an Overweight rating on the shares. The firm ...

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $243.45 which represents a slight increase of $2.98 or 1.24% from the prior close of $240.47. The stock opened at $239 and ...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, ...

Becton, Dickinson and Company announced it repurchased $750M in BD stock to date in FY25. In addition, the board has authorized the company to ...

Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 98.2% in the ...

Becton Dickinson plans to invest more than $30M in 2025 to expand its manufacturing capacity for IV lines at its Utah plant.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Atomi Financial Group Inc. lifted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 25.3% in the ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...